6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes

A process for preparing a compound of formula (I)

• and pharmaceutically acceptable salts, tautomers, or stereoisomers thereof, wherein
• R1 is aryl or heteroaryl, said aryl and said heteroaryl being mono- or bicyclic and optionally substituted with one or more of R5, R6, R7, and R8;
• R2, R3, and R4 are independently selected from hydrogen, C1-C3haloalkyl, and C1-C3alkyl;
• R5, R6, R7, and R8 are independently selected from halogen, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkyl, amino, —NHSO2R9, hydroxy, phenyl, and a monocyclic heteroaryl;
• and
• R9 is C1-C6haloalkyl or C1-C3alkyl;
• the process comprising:
• reacting a compound of formula (III):
• with a deprotecting agent to produce the compound of formula (I),
• optionally in the presence of R2-I when R2 is C1-C3haloalkyl or C1-C3alkyl;
• wherein
• R10 is F, OCH3, OC(CH3)3, or OSiR′R″R′″ and R′, R″, and R′″ are independently aryl or alkyl;
• and
• R1, R3, and R4 are defined as above for the compound of formula (I).